Premium
CD10 and Bcl‐2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large‐cell lymphoma with very good or very poor prognoses
Author(s) -
Biasoli I,
Morais J C,
Scheliga A,
Milito C B,
Romano S,
Land M,
Pulcheri W,
Spector N
Publication year - 2005
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2005.02099.x
Subject(s) - international prognostic index , medicine , hazard ratio , diffuse large b cell lymphoma , oncology , lymphoma , proportional hazards model , immunohistochemistry , confidence interval
Aims : Diffuse large B‐cell lymphoma (DLBCL) is characterized by marked biological heterogeneity. The identification of reproducible parameters that can be combined with the International Prognostic Index (IPI) to better predict outcome could lead to the development of effective risk‐adaptive strategies. Methods and results : Bcl‐2 and CD10 expression was determined by immunohistochemistry. The impact of the positivity on survival was evaluated in combination with the IPI in 86 patients with a confirmed diagnosis of DLBCL. Patients were divided according to the IPI into low‐risk (no to two factors) or high‐risk (three to five factors) groups. Positivity rates were 25% for CD10 and 42% for Bcl‐2. In a Cox analysis, the high‐risk IPI group [hazard ratio (HR) 5.98, P < 0.0001) and Bcl‐2 expression (HR 2.43, P = 0.02) were independent poor prognostic factors, and expression of CD10 (HR 0.41, P = 0.052) predicted a favourable outcome. Among patients in the low‐risk IPI group, CD10 positivity was associated with an excellent 8‐year overall survival (92% versus 45%, P = 0.06). In the high‐risk IPI group, Bcl‐2 positivity identified a subgroup with invariably fatal disease. Conclusions : The expression of CD10 in the low‐risk IPI group, and the expression of Bcl‐2 in the high‐risk IPI group can identify two subgroups of patients who might benefit from new risk‐adaptive treatment approaches.